Rashi Yadav received her Master’s degree from Panjab University, India and her Ph.D. from Michigan Technological University, Houghton. Her Ph.D. thesis focused on assessing the immunogenicity of HPV-L2 based VLPs vaccine against various HPV types causing cancer. After graduating, she pivoted to cancer immunotherapy, where she worked on OX40 and other immunotherapeutic agents to understand their mechanism of action. Rashi is currently focused on the role of tissue resident lymphocytes in early cancer development.